Beta-adrenergic blockade decreases coronary collateral blood flow in patients with coronary artery disease

Z S Kyriakides1, T Kolettis, A Antoniadis

  • 1Second Department of Cardiology, Onassis Cardiac Surgery Center, Athens, Greece. zskyr@otenet.gr, elbee@ath.forthnet.gr

Insights

Beta-adrenergic blockade, administered locally, reduces coronary collateral blood flow, potentially worsening ischemia. However, it also lessens myocardial ischemia during coronary angioplasty procedures.

Area of Science:

  • Cardiology
  • Pharmacology

Background:

  • The impact of beta-adrenergic blockade on coronary collateral blood flow remains unclear.
  • Coronary collateral circulation is vital for supplying blood to ischemic heart muscle.

Purpose of the Study:

  • To investigate the acute effects of beta-adrenergic blockade on coronary collateral blood flow.
  • To assess the influence of propranolol on myocardial ischemia during coronary angioplasty.

Main Methods:

  • Fifteen patients with stable angina undergoing coronary angioplasty were studied (Part A).
  • Intracoronary propranolol was administered, and collateral flow velocity was measured using a Doppler guidewire during balloon inflations.
  • Ten controls received saline infusion.
  • In Part B, the effect of intracoronary propranolol on coronary artery area was assessed in 10 patients.

Main Results:

  • Intracoronary propranolol administration decreased heart rate, velocity time integral, and ST elevation during balloon inflations.
  • These changes were not observed in the saline control group.
  • Propranolol did not significantly alter coronary artery lumen area.

Conclusions:

  • Intracoronary beta-adrenergic blockade reduces coronary collateral blood flow, potentially exacerbating the ischemic area.
  • Despite reducing collateral flow, beta-adrenergic blockade ameliorates myocardial ischemia during coronary angioplasty.

Related Concept Videos

Antianginal Drugs: Nitrates and β-Blockers01:16

Antianginal Drugs: Nitrates and β-Blockers

In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates,  such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers01:27

Adrenergic Antagonists: Pharmacological Actions of β-Receptor Blockers

β-receptor blockers significantly impact the cardiovascular system by counteracting catecholamine-induced sympathetic responses. These medications decrease heart rate, contractility, and cardiac output, potentially leading to cardiac depression, life-threatening bradycardia, and death. Therapeutically, β-blockers function as mild antihypertensives and are utilized in treating angina pectoris and cardiac arrhythmias. However, nonselective β-blockers inhibit β2-receptors in bronchial smooth...
Adrenergic Antagonists: ɑ and β-Receptor Blockers01:31

Adrenergic Antagonists: ɑ and β-Receptor Blockers

Third-generation β-blockers, such as labetalol and carvedilol, represent a significant advancement in managing cardiovascular conditions. Unlike conventional β-blockers, which can induce peripheral vasoconstriction, third-generation drugs block α1 adrenoceptors. This promotes vasodilation through several mechanisms, such as increased nitric oxide production, inhibition of calcium ion entry, opening of potassium ion channels, and antioxidant action. Labetalol, for instance, is clinically...
Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers01:22

Adrenergic Antagonists: Pharmacological Actions of ɑ-Receptor Blockers

α-Adrenergic antagonists, known as α-blockers, exert their effects by inhibiting α-adrenoceptors, leading to specific physiological actions. α1-blockers and α2-blockers have distinct pharmacological actions and therapeutic applications.
α1-blockers: These drugs inhibit α1-adrenoceptors on smooth muscle cells, resulting in vasodilation. This vasodilation lowers blood pressure, making α1-blockers valuable in treating hypertension. Additionally, α1-blockers effectively address urinary obstruction...
Antihypertensive Drugs: Action of β1 Blockers01:17

Antihypertensive Drugs: Action of β1 Blockers

β1-receptors are primarily located in the heart and kidneys. In cardiac myocytes, these receptors interact with neurotransmitters released by the sympathetic nervous system during heightened activity or danger. As a result, β1-receptors get activated, initiating a series of biochemical processes. Excessive activation of beta receptors due to chronic stress can abnormally increase heart rate and contractility, resulting in high blood pressure or hypertension. To counteract this, β1-blockers...
Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers01:17

Adrenergic Antagonists: Chemistry and Classification of ɑ-Receptor Blockers

Adrenergic antagonists, or sympatholytics, inhibit adrenoceptor activation driven by catecholamines or agonists. Based on their adrenoceptor specificity, adrenergic blockers can be categorized into two primary groups: α-adrenergic blockers (α-blockers) and β-adrenergic blockers (β-blockers). α-blockers interact with α1 and α2 subtypes of α-adrenoceptors.
Nonselective α-blockers: Nonselective α-blockers contain haloalkylamine or imidazoline moieties. Phenoxybenzamine, with a haloalkylamine...